Patents by Inventor Thomas Emrich

Thomas Emrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230265177
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: December 29, 2022
    Publication date: August 24, 2023
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Publication number: 20230251270
    Abstract: Herein is reported a method for selecting an antibody with a systematic clearance in cynomolgus monkeys of less than 8 mL/kg/day comprising the steps of measuring the retention time of the antibody on performing an FcRn affinity chromatography with a positive linear pH gradient and on a heparin affinity chromatography with a positive linear conductivity/salt gradient, and selecting an antibody that has a relative retention time on the FcRn affinity chromatography column is less than 1.78 times the retention time difference between peaks 2 and 3 the retention time of preparation of an oxidized anti-Her3 antibody of SEQ ID NO: 03 and 04, and a relative retention time on the heparin affinity chromatography column is less than 0.87 times the retention time of an anti-pTau antibody of SEQ ID NO: 01 and 02.
    Type: Application
    Filed: April 21, 2023
    Publication date: August 10, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hubert Kettenberger, Wolfgang Richter, Laurent Lariviere, Thomas Kraft, Thomas Emrich
  • Patent number: 11668722
    Abstract: Herein is reported a method for selecting an antibody with a systematic clearance in cynomolgus monkeys of less than 8 mL/kg/day comprising the steps of measuring the retention time of the antibody on performing an FcRn affinity chromatography with a positive linear pH gradient and on a heparin affinity chromatography with a positive linear conductivity/salt gradient, and selecting an antibody that has a relative retention time on the FcRn affinity chromatography column is less than 1.78 times the retention time difference between peaks 2 and 3 the retention time of preparation of an oxidized anti-Her3 antibody of SEQ ID NO: 03 and 04, and a relative retention time on the heparin affinity chromatography column is less than 0.87 times the retention time of an anti-pTau antibody of SEQ ID NO: 01 and 02.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: June 6, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Hubert Kettenberger, Wolfgang Richter, Laurent Lariviere, Thomas Kraft, Thomas Emrich
  • Publication number: 20230147561
    Abstract: Implementations generally relate to metaverse content modality mapping. In some implementations, a method includes obtaining functionality developed for a first modality of a virtual environment. The method further includes mapping the functionality to a second modality of the virtual environment. The method further includes executing the functionality developed for the first modality based on user interaction associated with the second modality.
    Type: Application
    Filed: November 7, 2022
    Publication date: May 11, 2023
    Inventors: Erik Murphy-Chutorian, Nicholas Butko, Thomas Emrich, Joel Udwin, Rigel Gareth Benton, Christoph Michael Bartschat
  • Patent number: 11572404
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: February 7, 2023
    Assignee: Hoffman-La Rocher Inc.
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Publication number: 20220073593
    Abstract: Herein is reported a method for providing a modified antibody with improved in vivo half-live, comprising the modification of the Fc-region of the antibody by introducing one or more mutations that change the binding of the Fc-region to human FcRn until the (relative) retention time of the modified antibody in an FcRn affinity chromatography is increased for more than 1 minute but not more than 5 minutes compared to the parent antibody.
    Type: Application
    Filed: April 22, 2021
    Publication date: March 10, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas EMRICH, Hubert KETTENBERGER, Thomas KRAFT, Wolfgang RICHTER, Tilman SCHLOTHAUER
  • Publication number: 20210190795
    Abstract: Herein is reported a method for determining the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life comprising the steps of a) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a first sodium chloride concentration, and b) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a second sodium chloride concentration, whereby the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life is determined if the retention time determined in step a) and the retention time determined in step b) are substantially different.
    Type: Application
    Filed: January 26, 2021
    Publication date: June 24, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas Emrich, Hubert Kettenberger, Tilman Schlothauer, Angela Schoch
  • Publication number: 20210139571
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: September 17, 2020
    Publication date: May 13, 2021
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Patent number: 10822402
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: November 3, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Publication number: 20200217851
    Abstract: Herein is reported a method for selecting an antibody with a systematic clearance in cynomolgus monkeys of less than 8 mL/kg/day comprising the steps of measuring the retention time of the antibody on performing an FcRn affinity chromatography with a positive linear pH gradient and on a heparin affinity chromatography with a positive linear conductivity/salt gradient, and selecting an antibody that has a relative retention time on the FcRn affinity chromatography column is less than 1.78 times the retention time difference between peaks 2 and 3 the retention time of preparation of an oxidized anti-Her3 antibody of SEQ ID NO: 03 and 04, and a relative retention time on the heparin affinity chromatography column is less than 0.87 times the retention time of an anti-pTau antibody of SEQ ID NO: 01 and 02.
    Type: Application
    Filed: October 18, 2019
    Publication date: July 9, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hubert Kettenberger, Wolfgang Richter, Laurent Lariviere, Thomas Kraft, Thomas Emrich
  • Patent number: 10040843
    Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: August 7, 2018
    Assignee: ROCHE GLYCART AG
    Inventors: Lydia Jasmin Duerner, Thomas Emrich, Jens Fischer, Ralf Hosse, Ekkehard Moessner, Pablo Umana, Daigen Xu
  • Publication number: 20180079804
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: December 5, 2017
    Publication date: March 22, 2018
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Patent number: 9862763
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: January 9, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Publication number: 20170227547
    Abstract: Herein is reported a method for determining the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life comprising the steps of a) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a first sodium chloride concentration, and b) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of a second sodium chloride concentration, whereby the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life is determined if the retention time determined in step a) and the retention time determined in step b) are substantially different.
    Type: Application
    Filed: September 20, 2016
    Publication date: August 10, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas Emrich, Hubert Kettenberger, Tilman Schlothauer, Angela Schoch
  • Publication number: 20160376352
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: June 22, 2016
    Publication date: December 29, 2016
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Publication number: 20160340413
    Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: April 27, 2016
    Publication date: November 24, 2016
    Inventors: Lydia Jasmin Duerner, Thomas Emrich, Jens Fischer, Ralf Hosse, Ekkehard Moessner, Pablo Umana, Daigen Xu
  • Patent number: 9346872
    Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: May 24, 2016
    Assignee: ROCHE GLYCART AG
    Inventors: Lydia Jasmin Duerner, Thomas Emrich, Jens Fischer, Ralf Hosse, Ekkehard Moessner, Pablo Umana, Daigen Xu
  • Patent number: 9273361
    Abstract: The present invention relates to a method for the specific detection and/or identification of Enterococcus species, in particular Enterococcus faecalis and/or Enterococcus faecium, using new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region. The present invention relates also to said new nucleic acid sequences derived from the ITS region, between the 16S and 23S ribosomal ribonucleic acid (rRNA) or rRNA genes, to be used for the specific detection and/or identification of Enterococcus species, in particular of Enterococcus faecalis and/or Enterococcus faecium, in a biological sample. It relates also to nucleic acid primers to be used for the amplification of said spacer region of Enterococcus species in a sample.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: March 1, 2016
    Assignees: FUJIREBIO EUROPE N.V., ROCHE DIAGNOSTICS GMBH
    Inventors: Hilde De Henau, Joachim Van Crombruggen, Geert Jannes, Gerd Haberhausen, Thomas Emrich
  • Publication number: 20150218244
    Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). More particularly, the invention concerns fusion proteins of antibodies and mutant IL-10 that exhibit improved properties for use as therapeutic agents, e.g. in the treatment of inflammatory diseases. In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 6, 2015
    Inventors: Thomas Emrich, Pablo Umana, Ekkehard Moessner, Ralf Hosse, Jens Fischer, Lydia Jasmin Hanisch, Daigen Xu
  • Patent number: 8945850
    Abstract: The present invention relates to a method for the specific detection and/or identification of Staphylococcus species, in particular Staphylococcus aureus, using new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region. The present invention relates also to said new nucleic acid sequences derived from the ITS region, between the 16S and 23S ribosomal ribonucleic acid (rRNA) or rRNA genes, to be used for the specific detection and/or identification of Staphylococcus species, in particular of S. aureus, in a biological sample. It relates also to nucleic acid primers to be used for the amplification of said spacer region of Staphylococcus species in a sample.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: February 3, 2015
    Assignees: Fujirebio Europe N.V., Roche Diagnostics GmbH
    Inventors: Sofie Claeys, Geert Jannes, Gerd Haberhausen, Thomas Emrich, Lia Verdoodt